Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 199

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Nuclear factor kappa B–mediated CD47 up‐regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice

Lo, Jessica, Lau, Eunice Yuen Ting, Ching, Rachel Hiu Ha, Cheng, Bowie Yik Ling, Ma, Mark Kin Fai, Ng, Irene Oi Lin, Lee, Terence Kin Wah · 2015 · Hepatology

Abstract

Sorafenib is a new standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, the survival benefit of this treatment is modest, partly owing to drug resistance. Recent evidence has demonstrated the existence of tumor‐initiating cells (T‐ICs) as the culprit for treatment resistance. To examine whether sorafenib resistance was a result of the presence of liver T‐ICs, we developed sorafenib‐resistant HCC cells both in vitro and in vivo through continuous exposure to sorafenib. Using these models, we found that sorafenib‐resistant clones demonstrated enhanced T‐IC properties, including tumorigenicity, self‐renewal, and invasiveness. In addition, several T‐IC markers were found to be up‐regulated, among which CD47 was found to be most significant. Using chromatin immunoprecipitation assays and expression analyses, CD47 expression was found to be regulated by nuclear factor kappa B (NF‐κB) through a specific response element in the promoter of CD47, and the site occupancy and expression were increased and decreased upon stimulation and inhibition of NF‐κB, respectively. Consistently, NF‐κB was activated in sorafenib‐resistant HCC cells, and this finding was confirmed in clinical HCC samples, which showed a positive correlation between NF‐κB and CD47 expression. Functional characterization of CD47 in sorafenib‐resistant HCC cells was evaluated using a lentivirus‐based knockdown approach and showed increased sensitization to sorafenib upon CD47 knockdown. Furthermore, blockade of CD47 using anti‐CD47 antibody (Ab) showed a similar effect. Using a patient‐derived HCC xenograft mouse model, we found that anti‐CD47 Ab (500 μg/mouse) in combination with sorafenib (100 mg/kg, orally) exerted synergistic effects on tumor suppression, as compared with sorafenib and anti‐CD47 Ab alone. Conclusions: NF‐κB‐mediated CD47 up‐regulation promotes sorafenib resistance, and targeting CD47 in combination with sorafenib is an attractive therapeutic regimen for the treatment of HCC patients. (H epatology 2015;62:534–545

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.27859

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 199

Metadata

Authors
Lo, J., Lau, E. Y. T., Ching, R. H. H., Cheng, B. Y. L., Ma, M. K. F., Ng, I. O. L., & Lee, T. K. W.
Venue
Hepatology
Published
2015-06-03
Volume
62
Issue
2
Pages
534-545
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W1724078287
Cited by
199
References
5
FWCI
7.16
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.